Compounds > nornitrogen mustard
Page last updated: 2024-12-05

nornitrogen mustard

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nornitrogen mustard: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9533
CHEMBL ID913
CHEBI ID37599
SCHEMBL ID24674
MeSH IDM0046161

Synonyms (46)

Synonym
nor-n-mustard
ccris 807
nor-mechlorethamine
nor-mustard
nor-nitrogen mustard
di(2-chloroethyl)amine
n,n-bis-(beta-chloraethyl)-amin [german]
brn 0605316
ethanamine, 2-chloro-n-(2-chloroethyl)-
ai3-26386
nh-lost [german]
diethylamine, 2,2'-dichloro-
2,2'-dichlorodiethylamine
334-22-5
nh-lost
2-chloro-n-(2-chloroethyl)ethanamine
bis(chloroethyl)amine
nornitrogen mustard
bis(2-chloroethyl)amine
CHEBI:37599 ,
CHEMBL913
AKOS000120484
unii-ihv3i38uxh
ihv3i38uxh ,
n,n-bis-(beta-chloraethyl)-amin
n,n-bis(.beta.-chloroethyl)amine
.beta.,.beta.-dichlorodiethylamine
bis(.beta.-chloroethyl)amine
n,n-bis(2-chloroethyl)amine
n,n-bis(2-chloroethane)amine
bis-(beta-chloroethyl)-amine
bis[2-chloroethyl]amine
bis-(2-chloroethyl) amine
bis-(2-chloro-ethyl)-amine
bis-(2-chloroethyl)amine
SCHEMBL24674
bis-.beta.-chloroethylamine
n,n-bis-(.beta.-chloroethyl)-amine
bis(beta-chloroethyl)amine
AC-22676
DTXSID60187028
mfcd00128968
Q27117201
AB10357
EN300-33963
STL197468

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Treatment of yeast cells with the chemically activated form of CP (4-hydroperoxy-CP, 4-OOH-CP) and with several potentially toxic cleavage products revealed that cytotoxicity is closely linked to the formation of DNA interstrand cross-links and to DNA fragmentation."( Toxicity, interstrand cross-links and DNA fragmentation induced by 'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard.
Brendel, M; Fleer, R, 1982)		0.26
" On the other hand, acrolein was most toxic to cell proliferation and most active in inducing chromosome breakage."( Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro.
Arrighi, FE; Au, W; Kopnin, B; Sokova, OI, 1980)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrogen mustardCompounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Cyclophosphamide Action Pathway922
Cyclophosphamide Metabolism Pathway922

Bioassays (34)

Assay IDTitleYearJournalArticle
AID133551Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells after 4 hr at the concentration of 1x10E4M for experiment X1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133417Evaluated for the percent inhibition uptake of radiolabeled leucine as a measure of inhibition of protein synthesis i.e., cell death against the SV40-transformed 3T3 cells at 4 hr at the concentration of 3Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133559Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 1.5Mx10E4 for expt VI1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133564Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 28Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133566Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 3Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133565Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 3Mx10E4 for expt VI1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133700Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at the concentration of 3*10-4M after 4 hr1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133558Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells after 4 hr at the concentration of 6x10E4M for experiment XI1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133570Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 8Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133548Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the L1210 cells after 4 hr at the concentration of 1.5x10E4M1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133546Evaluated for the percent inhibition uptake of radiolabeled leucine as a measure of inhibition of protein synthesis i.e., cell death against the SV40-transformed 3T3 cells at 4 hr at the concentration of 6Mx10E4 for expt VIII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133701Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at the concentration of 3*10-4M after 6 hr1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133569Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 6Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID140330Toxicity was evaluated for the compound at a concentration of 0.208 mM against P-185 Mastocytoma.1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133698Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at the concentration of 3*10-4M after 24 hr1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133568Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 6Mx10E4 for expt VI1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133561Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 17Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133554Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells after 4 hr at the concentration of 3x10E4M for experiment X1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133702Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at the concentration of 3*10-4M after 8 hr1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133547Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the L1210 cells after 4 hr at the concentration of 0.5x10E4M1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133552Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells after 4 hr at the concentration of 1x10E4M for experiment XI1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133555Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells after 4 hr at the concentration of 3x10E4M for experiment XI1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133549Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the L1210 cells after 4 hr at the concentration of 3.0x10E4M1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133544Evaluated for the percent inhibition uptake of radiolabeled leucine as a measure of inhibition of protein synthesis i.e., cell death against the SV40-transformed 3T3 cells at 4 hr at the concentration of 3Mx10E4 for expt VIII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID102018Cytotoxicity of compound was determined against Lo Vo colon cancer cells2000Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard.
AID133545Evaluated for the percent inhibition uptake of radiolabeled leucine as a measure of inhibition of protein synthesis i.e., cell death against the SV40-transformed 3T3 cells at 4 hr at the concentration of 6Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID140333Toxicity was evaluated for the compound at a concentration of 0.281 mM against P-185 Mastocytoma.1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133560Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 10Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID129108Toxicity toward P-815 Mastocytoma cells after 5 hr was determined as percent of [51Cr]- release from labeled cells as a measure of cell death at a concentration of 0.208 mM (expt IV)1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133414Evaluated for the percent inhibition uptake of radiolabeled leucine as a measure of inhibition of protein synthesis i.e., cell death against the SV40-transformed 3T3 cells at 4 hr at the concentration of 17Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133557Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells after 4 hr at the concentration of 6x10E4M for experiment X1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID129111Toxicity toward P-815 Mastocytoma cells after 5 hr was determined as percent of [51Cr]- release from labeled cells as a measure of cell death at a concentration of 0.218 mM (expt V)1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133699Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at the concentration of 3*10-4M after 3h1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
AID133567Evaluated for the percent inhibition uptake of radiolabeled thymidine as a measure of inhibition of cell division against the SV40-transformed 3T3 cells at 4 hr at the concentration of 4Mx10E4 for expt VII1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Lysosomotropic agents. 4. Carbobenzoxyglycylphenylalanyl, a new protease-sensitive masking group for introduction into cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (63.16)18.7374
1990's4 (21.05)18.2507
2000's2 (10.53)29.6817
2010's1 (5.26)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.15 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
taurine
[no description available]		1.9710amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		2.0110aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
ifosfamide
[no description available]		1.9710ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		2.8840nitrogen mustard;
organochlorine compound		alkylating agent
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		1.9710amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		1.9910L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
methylene chloride
Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.		1.9910chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
acrolein
[no description available]		7.3620enalherbicide;
human xenobiotic metabolite;
toxin
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		1.98101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9910dihydrogen
carboxyphosphamide
carboxyphosphamide: metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation; structure		1.9810nitrogen mustard
4-ketocyclophosphamide
4-ketocyclophosphamide: metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation; structure		1.9810nitrogen mustard
1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea
[no description available]		1.9710
trofosfamide
trofosfamide: cyclophosphamide analog; structure		1.9710ifosfamides
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		2.6830carbamate ester;
oxazolidinone		metabolite
phosphoramide mustard
[no description available]		2.6930nitrogen mustard;
phosphorodiamide
carbobenzoxyglycylphenylalanine amide
carbobenzoxyglycylphenylalanine amide: used as substrate for metalloendopeptidases; RN given refers to (L)-isomer		1.9610
dechloroethylcyclophosphamide
dechloroethylcyclophosphamide: structure given in first source; RN given refers to parent cpd		1.9810phosphorodiamide
phosphoramide
phosphoramide: RN given refers to triamide. phosphoramide : A compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2).		6.9710
pentafluorophenylisothiocyanate
pentafluorophenylisothiocyanate: coupling agent used in Edman degradation		1.9910
estramustine
Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.		2.663017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.0110L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
oxazolone
Oxazolone: Immunologic adjuvant and sensitizing agent.		1.9910
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.0110cysteiniumfundamental metabolite
perfosfamide
[no description available]		1.9610
carbobenzoxyglycylphenylalanine
carbobenzoxyglycylphenylalanine: used as substrate for carboxypeptidase B; RN given refers to (L-Phe)-isomer		1.9610
guanine
[no description available]		2.38202-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		1.9710guanosines;
purines D-ribonucleoside		fundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9610
Experimental Neoplasms
[description not available]		01.9610
Cancer of Colon
[description not available]		0210
Colonic Neoplasms
Tumors or cancer of the COLON.		0210
Abnormalities, Autosome
[description not available]		02.3620
Carcinoma, Anaplastic
[description not available]		02.3620
Cancer of Prostate
[description not available]		02.6630
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.3620
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.6630
Benign Neoplasms
[description not available]		02.6630
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.6630
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9910